proxyvotesnow.com

Home › Companies › APOGEE THERAPEUTICS INC. › 2024-2025

APOGEE THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and APOGEE THERAPEUTICS INC.’s Form 8-K, filed June 23, 2025 (Item 5.07 on EDGAR). Page generated October 25, 2026.

  • 5Reported items
  • 182Asset managers
  • 1,147Fund votes
  • June 17, 2025Meeting date

Results at a glance

Meeting of June 17, 2025: 4 items on APOGEE THERAPEUTICS INC.’s Form 8-K, filed June 23, 2025: 1 approved · 3 without a stated outcome.

Material dissent

None.

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2024-2025 2025-2026

Explore APOGEE THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by APOGEE THERAPEUTICS INC.

These tallies are APOGEE THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

APOGEE THERAPEUTICS INC. — official shareholder meeting results, meeting held June 17, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Lisa Bollinger, M.D. 35,139,585--4,250,286 --1,795,017 —Not verified—
Elect Director: Tomas Kiselak 39,235,384--154,487 --1,795,017 —Not verified—
Elect Director: Nimish Shah 25,782,554--13,607,317 --1,795,017 —Not verified—
2. Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 41,155,5603,09926,229 ---- 99.9%Approved—

Source: APOGEE THERAPEUTICS INC., Form 8-K, filed with the SEC on June 23, 2025 — read the filing on EDGAR.

How asset managers voted at the APOGEE THERAPEUTICS INC. 2024-2025 meeting

Each item below shows how the 182 asset managers that disclosed a APOGEE THERAPEUTICS INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of APOGEE THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Elect Director: Lisa Bollinger, M.D.

Outcome not verifiedDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

94% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2028: Lisa Bollinger, M.D.

The 65 asset managers below reported 13,539,610 for, 828,981 withheld, 493,816 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 13,539,610ABSTAIN: 493,816WITHHOLD: 828,981
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Lisa Bollinger, M.D.” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust7,3630 424,1280Abstain
DRIEHAUS MUTUAL FUNDS00 0323,047Withhold
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital7580 0211,159Withhold
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan132,7480 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust9990 083,494Withhold
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial27,8000 023,306Mixed
TRUST FOR PROFESSIONAL MANAGERS00 49,9830Abstain
Goldman Sachs00 047,996Withhold

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

2. Elect Director: Nimish Shah

Outcome not verifiedDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

63% of fund votes cast · no official result

FORWITHHOLD
Details: description as filed, votes by 65 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2028: Nimish Shah

The 65 asset managers below reported 8,683,362 for, 5,007,415 withheld, 1,171,630 abstained. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 8,683,362ABSTAIN: 1,171,630WITHHOLD: 5,007,415
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Nimish Shah” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity00 03,975,225Withhold
T. Rowe Price622,3010 00For
BlackRock00 594,9820Abstain
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust00 431,4910Abstain
DRIEHAUS MUTUAL FUNDS00 0323,047Withhold
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital7580 0211,159Withhold
Capital Group193,8950 00For
Equitable143,1810 029,567Mixed
JPMorgan132,7480 00For
Columbia Threadneedle00 0106,279Withhold
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust00 084,493Withhold
QUANTITATIVE MASTER SERIES LLC00 65,1820Abstain
BNY Mellon58,1850 00For
Lincoln Financial00 051,106Withhold
TRUST FOR PROFESSIONAL MANAGERS00 49,9830Abstain
Goldman Sachs00 047,996Withhold

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

3. Elect Director: Tomas Kiselak

Outcome not verifiedDIRECTOR ELECTIONS

Combines 3 wordings of this item as funds reported it.

99.8% of fund votes cast · no official result

FOR
Details: description as filed, votes by 65 asset managers

Description as filed by funds: Election of Class II Directors for terms expiring in 2028: Tomas Kiselak

The 65 asset managers below reported 14,847,293 for, 15,114 withheld. The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

FOR: 14,847,293WITHHOLD: 15,114
Largest asset managers voting on “Election of Class II Directors for terms expiring in 2028: Tomas Kiselak” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust431,4910 00For
DRIEHAUS MUTUAL FUNDS323,0470 00For
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital211,9170 00For
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan132,7480 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust84,4930 00For
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial51,1060 00For
TRUST FOR PROFESSIONAL MANAGERS49,9830 00For
Goldman Sachs47,9960 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

4. VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.

No official matchFund totals may overlapSECTION 14A SAY-ON-PAY VOTES

Combines 3 wordings of this item as funds reported it.

100% Fund and manager reports combined; may count the same shares twice · no official result

1 YEAR
Details: votes by 182 asset managers

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.

Fund voting reports: 65 asset managers voting on “VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard00 00--
Fidelity00 00--
T. Rowe Price00 00--
BlackRock00 00--
FRANKLIN STRATEGIC SERIES00 00--
AllianceBernstein00 00--
Bridge Builder Trust00 00--
DRIEHAUS MUTUAL FUNDS00 00--
Charles Schwab00 00--
JANUS INVESTMENT FUND00 00--
AB DISCOVERY GROWTH FUND, INC.00 00--
Hartford00 00--
Victory Capital00 00--
Capital Group00 00--
Equitable00 00--
JPMorgan00 00--
Columbia Threadneedle00 00--
TIAA00 00--
Principal00 00--
Brinker Capital Destinations Trust00 00--
QUANTITATIVE MASTER SERIES LLC00 00--
BNY Mellon00 00--
Lincoln Financial23,3060 00For
TRUST FOR PROFESSIONAL MANAGERS00 00--
Goldman Sachs00 00--

Fund voting reports, all 65 managers: 28,728 for, 12,502 abstained, 14,821,177 1 year. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 137 asset managers voting on “VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS' COMPENSATION.” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Fidelity00 00--
Wellington00 00--
RTW INVESTMENTS, LP00 00--
Fairmount Funds Management LLC00 00--
VR Adviser, LLC00 00--
DRIEHAUS CAPITAL MANAGEMENT LLC00 00--
AllianceBernstein00 00--
BlackRock00 00--
Woodline Partners LP00 00--
FRANKLIN ADVISERS INC00 00--
T. Rowe Price00 00--
PERCEPTIVE ADVISORS LLC692,1760 00For
Janus Henderson00 00--
Siren, L.L.C.00 00--
Paradigm Biocapital Advisors LP00 00--
State Street00 00--
Affinity Asset Advisors, LLC00 00--
Victory Capital00 00--
Commodore Capital LP00 00--
Charles Schwab00 00Not Voted
Capital Group00 00--
Northern Trust00 00--
Blackstone Inc.00 00--
Point7200 00--
UI BVK Kapitalverwaltungsgesellschaft mbH00 00--

Institutional-manager reports, all 137 managers: 692,176 for, 44 not voted, 30,015,933 1 year. Showing the 25 largest; see all in the interactive database.

5. 2. Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent…

Official resultAUDIT-RELATEDReported outcome: Approved

99.9% Approved · of votes cast

FOR 99.9%
FOR: 41,155,560AGAINST: 3,099
Details: description as filed, official tally, votes by 65 asset managers

Description as filed by funds: RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE YEAR ENDING DECEMBER 31, 2025.

APOGEE THERAPEUTICS INC.’s own tally for this item (“2. Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025”): 41,155,560 for, 3,099 against — passed, per its Form 8-K filed June 23, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of Independent Auditor Appointment The appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2025 was ratified as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 65 asset managers below reported 14,849,905 for, 12,502 abstained.

FOR
FOR: 14,849,905ABSTAIN: 12,502
Largest asset managers voting on “RATIFICATION OF THE APPOINTMENT OF ERNST & YOUNG LLP AS THE COMPANY'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING” at APOGEE THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
Vanguard5,177,3500 00For
Fidelity3,975,2250 00For
T. Rowe Price622,3010 00For
BlackRock594,9820 00For
FRANKLIN STRATEGIC SERIES538,0960 00For
AllianceBernstein438,3410 00For
Bridge Builder Trust431,4910 00For
DRIEHAUS MUTUAL FUNDS323,0470 00For
Charles Schwab276,7930 00For
JANUS INVESTMENT FUND275,6390 00For
AB DISCOVERY GROWTH FUND, INC.250,9010 00For
Hartford225,0770 00For
Victory Capital211,9170 00For
Capital Group193,8950 00For
Equitable172,7480 00For
JPMorgan132,7480 00For
Columbia Threadneedle106,2790 00For
TIAA104,0070 00For
Principal87,4490 00For
Brinker Capital Destinations Trust84,4930 00For
QUANTITATIVE MASTER SERIES LLC65,1820 00For
BNY Mellon58,1850 00For
Lincoln Financial51,1060 00For
TRUST FOR PROFESSIONAL MANAGERS49,9830 00For
Goldman Sachs47,9960 00For

Showing the 25 largest of 65 asset managers. See all 65 in the interactive database.

Largest APOGEE THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 58,304,801 shares outstanding at the time of that meeting.

Fund voting reports: top APOGEE THERAPEUTICS INC. shareholders by shares voted on “VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS'…”, 2024-2025
#Asset manager % of shares outstanding
1Vanguard 8.88%
2Fidelity 6.82%
3T. Rowe Price 1.07%
4BlackRock 1.02%
5FRANKLIN STRATEGIC SERIES 0.92%
6AllianceBernstein 0.75%
7Bridge Builder Trust 0.74%
8DRIEHAUS MUTUAL FUNDS 0.55%
9Charles Schwab 0.47%
10JANUS INVESTMENT FUND 0.47%
Institutional-manager reports: top APOGEE THERAPEUTICS INC. shareholders by shares voted on “VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS'…”, 2024-2025
#Asset manager % of shares outstanding
1Fidelity 11.91%
2Wellington 8.48%
3RTW INVESTMENTS, LP 4.65%
4Fairmount Funds Management LLC 3.51%
5VR Adviser, LLC 3.00%
6DRIEHAUS CAPITAL MANAGEMENT LLC 2.51%
7AllianceBernstein 2.02%
8BlackRock 1.60%
9Woodline Partners LP 1.48%
10FRANKLIN ADVISERS INC 1.46%

Reported APOGEE THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

APOGEE THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder % outstanding Disclosure
FMR (Fidelity) 12.85% 13F
Fairmount Funds Management LLC 11.51% 13D
Wellington Management 9.41% 13F
BlackRock 4.99% 13F
RTW Investments, LP 4.65% 13G
Vanguard Group 3.57% 13F
State Street 2.25% 13F
JPMorgan Chase 1.65% 13F
Franklin Templeton 1.50% 13F
Geode Capital 1.43% 13F

Percentages above are of 58,304,801 shares outstanding, as reported by APOGEE THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from APOGEE THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 25, 2026; a live search always shows the current data.

At APOGEE THERAPEUTICS INC.'s shareholder meeting held June 17, 2025, in the 2024-2025 proxy season, 182 asset managers reported how they voted in their SEC Form N-PX filings, covering 1,147 separate fund positions. Their filings are grouped here into 5 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. APOGEE THERAPEUTICS INC.'s own Form 8-K tally for this meeting is published below, but no row in it could be matched to the most widely held item, so this page states no certified outcome for that item. On that item — VOTE ON THE FREQUENCY OF FUTURE ADVISORY VOTES TO APPROVE OUR NAMED EXECUTIVE OFFICERS'… — the reporting funds and managers cast 100% of the shares they voted in favour (FOR divided by FOR plus AGAINST plus WITHHELD; abstained and unvoted shares are excluded because neither took a side). Fund and manager reports are combined in it and may count the same shares twice: it adds fund reports to institutional-manager reports, which can cover the same shares. It is not the company's certified result.

APOGEE THERAPEUTICS INC. proxy season coverage: 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.